[1]刘 静.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响[J].医学信息,2018,31(13):137-138,141.[doi:10.3969/j.issn.1006-1959.2018.13.040]
　LIU Jing.Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity[J].Journal of Medical Information,2018,31(13):137-138,141.[doi:10.3969/j.issn.1006-1959.2018.13.040]
点击复制

利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者 血糖控制及体质量指数的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年13期
页码:
137-138,141
栏目:
药物与临床
出版日期:
2018-07-01

文章信息/Info

Title:
Effect of Liraglutide Combined with Basal Insulin on Blood Glucose Control and Body Mass Index in Newly Diagnosed Type 2 Diabetes Patients with Obesity
文章编号:
1006-1959（2018）13-0137-03
作者:
刘 静
佳木斯市中心医院内分泌科，黑龙江 佳木斯 154002
Author(s):
LIU Jing
Department of Endocrinology,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China
关键词:
利拉鲁肽; 基础胰岛素; 初诊2型糖尿病; 肥胖
Keywords:
Key words：Liraglutide; Basal insulin; Newly diagnosed type 2 diabetes; Obesity
分类号:
R587.1；R589.2
DOI:
10.3969/j.issn.1006-1959.2018.13.040
文献标志码:
A
摘要:
目的 观察利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者血糖控制及体质量指数的影响。方法 收集我院自2016年12月~2018年1月收治的94例初诊2型糖尿病合并肥胖患者作为观察对象，按数字奇偶法分为研究组与对照组，每组47例。对照组给予基础胰岛素治疗，研究组则在对照组的基础上加用利拉鲁肽治疗。观察并比较两组血糖控制及体质量指数变化情况，低血糖事件发生率。结果 治疗后，两组血糖指标水平及BMI均低于治疗前，且研究组降低幅度大于对照组，差异具有统计学意义（P＜0.05）。研究组低血糖事件发生率为2.13%，低于对照组的14.89%，差异具有统计学意义（P＜0.05）。结论 利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者疗效确切，可有效控制血糖，调节体质量指数。
Abstract:
Abstract：Objective To observe the effects of liraglutide combined with basal insulin on blood glucose control and body mass index in newly diagnosed type 2 diabetes patients with obesity.Methods A total of 94 patients with newly diagnosed type 2 diabetes mellitus complicated with obesity admitted to our hospital from December 2016 to January 2018 were enrolled.The patients were divided into study group and control group according to the numerical parity method,with 47 cases in each group.The control group was given basal insulin treatment,and the study group was treated with liraglutide on the basis of the control group.Observe and compare the changes in blood glucose control and body mass index,the incidence of hypoglycemic events.Results After treatment,the blood glucose levels and BMI of the two groups were lower than before treatment,and the reduction of the study group was greater than that of the control group,the difference was statistically significant(P<0.05).The incidence of hypoglycemia in the study group was 2.13%,which was lower than that in the control group 14.89%,and the difference was statistically significant(P<0.05).Conclusion Liraglutide combined with basal insulin is effective in the treatment of newly diagnosed type 2 diabetes mellitus patients with obesity. It can effectively control blood sugar and regulate body mass index.

参考文献/References:

[1]张星,魏琦,温维琴,等.利拉鲁肽对2型糖尿病合并肥胖患者血清趋化素和胰岛素抵抗的影响[J].检验医学与临床,2017,14(6):800-802. [2]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2010年版)[J].中国糖尿病杂志,2012,20(1):1-36. [3]杨帆,李钶,蒋晓岚,等.利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究[J].重庆医学,2016,45(25):3493-3495. [4]霍丽梅,费雯婕,宋光耀,等.利拉鲁肽治疗2型糖尿病合并肥胖疗效观察[J].中国药师,2017,20(12):2218-2220. [5]贺菲菲,宋民喜,徐琳,等.利拉鲁肽联合基础胰岛素对初诊2型糖尿病合并肥胖患者血糖控制、血脂代谢及氧化应激的影响[J].海南医学院学报,2018,24(2):173-176.

相似文献/References:

[1]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Journal of Medical Information,2018,31(13):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[2]房 芳,于 宏.利拉鲁肽联合二甲双胍治疗2型糖尿病的疗效观察[J].医学信息,2022,35(16):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
　FANG Fang,YU Hong.Effect of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(13):141.[doi:10.3969/j.issn.1006-1959.2022.16.036]
[3]曾小兵,朱长东,谢宝强.利拉鲁肽对首诊2型糖尿病患者血糖、血脂及T细胞亚群的影响[J].医学信息,2019,32(22):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
　ZENG Xiao-bing,ZHU Chang-dong,XIE Bao-qiang.Effect of Liraglutide on Blood Glucose,Blood Lipids and T cell Subsets in Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2019,32(13):125.[doi:10.3969/j.issn.1006-1959.2019.22.041]
[4]马晓云.早期胰岛素强化联合不同治疗方案对新诊断T2DM的效果[J].医学信息,2020,33(16):163.[doi:10.3969/j.issn.1006-1959.2020.16.053]
　MA Xiao-yun.Effect of Early Insulin Intensive Combined with Different Treatment Schemes on Newly Diagnosed Type 2 Diabetes Patients[J].Journal of Medical Information,2020,33(13):163.[doi:10.3969/j.issn.1006-1959.2020.16.053]
[5]王晓洲,吴仰帆,栾晓军.利拉鲁肽对肥胖T2DM患者促炎-抗炎系统及左心舒张功能的影响[J].医学信息,2021,34(22):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
　WANG Xiao-zhou,WU Yang-fan,LUAN Xiao-jun.Effects of Liraglutide on Pro-inflammatory-anti-inflammatory System and Left Ventricular Diastolic Function in Obese T2DM Patients[J].Journal of Medical Information,2021,34(13):145.[doi:10.3969/j.issn.1006-1959.2021.22.045]
[6]陶 蕾,张宏江,范中阳.利拉鲁肽联合胰岛素治疗肥胖2型糖尿病的疗效[J].医学信息,2021,34(23):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
　TAO Lei,ZHANG Hong-jiang,FAN Zhong-yang.Effect of Liraglutide Combined with Insulin in the Treatment of Obesity Type 2 Diabetes Mellitus[J].Journal of Medical Information,2021,34(13):99.[doi:10.3969/j.issn.1006-1959.2021.23.028]
[7]张 彤.利拉鲁肽联合胰岛素治疗新诊断肥胖2型糖尿病的临床疗效及安全性[J].医学信息,2022,35(05):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]
　ZHANG Tong.Clinical Efficacy and Safety of Liraglutide Combined with Insulin in the Treatment of Newly Diagnosed Obese Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(13):159.[doi:10.3969/j.issn.1006-1959.2022.05.042]

更新日期/Last Update: 2018-07-01